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Impact of L-carnitine on plasma 
lipoprotein(a) concentrations: 
A systematic review and meta-
analysis of randomized controlled 
trials
Maria-Corina Serban1,2, Amirhossein Sahebkar3,4, Dimitri P. Mikhailidis5, Peter P. Toth6,7, 
Steven R. Jones7, Paul Muntner1, Michael J. Blaha7, Florina Andrica8, Seth S. Martin7, 
Claudia Borza2, Gregory Y.H. Lip9, Kausik K. Ray10, Jacek Rysz11, Stanley L. Hazen12 & 
Maciej Banach11
We aimed to assess the impact of L-carnitine on plasma Lp(a) concentrations through systematic 
review and meta-analysis of available RCTs. The literature search included selected databases up to 
31st January 2015. Meta-analysis was performed using fixed-effects or random-effect model according 
to I2 statistic. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence 
interval (CI). The meta-analysis showed a significant reduction of Lp(a) levels following L-carnitine 
supplementation (WMD: −8.82 mg/dL, 95% CI: −10.09, −7.55, p < 0.001). When the studies 
were categorized according to the route of administration, a significant reduction in plasma Lp(a) 
concentration was observed with oral (WMD: −9.00 mg/dL, 95% CI: −10.29, −7.72, p < 0.001) but not 
intravenous L-carnitine (WMD: −2.91 mg/dL, 95% CI: −10.22, 4.41, p = 0.436). The results of the meta-
regression analysis showed that the pooled estimate is independent of L-carnitine dose (slope: −0.30; 
95% CI: −4.19, 3.59; p = 0.878) and duration of therapy (slope: 0.18; 95% CI: −0.22, 0.59; p = 0.374). In 
conclusion, the meta-analysis suggests a significant Lp(a) lowering by oral L-carnitine supplementation. 
Taking into account the limited number of available Lp(a)-targeted drugs, L-carnitine might be an 
effective alternative to effectively reduce Lp(a). Prospective outcome trials will be required to fully 
elucidate the clinical value and safety of oral L-carnitine supplementation.
In 1963, Kåre Berg discovered lipoprotein(a) [Lp(a)] in human plasma, a low-density lipoprotein (LDL)-like lipo-
protein particle with atherogenic and thrombotic properties1. Lp(a) is composed by a central LDL-like lipoprotein 
core particle with apolipoprotein B (apoB) covalently bound to glycoprotein apo(a), resulting in differing struc-
ture, physical and chemical properties compared with LDL1,2. The levels of Lp(a) in human plasma are genetically 
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modulated, and Precocious Coronary Artery Disease (PROCARDIS) study showed that two Lp(a) single nucle-
otide polymorphisms (SNPs) accounted for 36% of variation in Lp(a) levels3. The levels of Lp(a) vary among 
populations; African descendants have increased Lp(a) levels as compared to Caucasians and Asian descendants4. 
However, different conditions such as diabetes, endocrine disorders, renal and liver failure or the acute-phase 
response might influence the synthesis or catabolism of Lp(a)5,6. The development of immunoassays to precisely 
measure Lp(a) levels in plasma was impeded by the structural complexity and size heterogeneity of Lp(a)3.
Many studies have shown that increased plasma Lp(a) levels are associated with coronary artery disease7,8, 
peripheral arterial disease9, cerebrovascular disease10, abdominal aortic aneurysm, aortic valve stenosis and calci-
fication11, and venous thromboembolism12. Moreover, elevated Lp(a) levels have been found to be associated with 
increased risks for major adverse cardiac events (MACE)13. The atherogenic impact influenced by the effective 
binding of oxidized phospholipids by Lp(a), the expression of adhesion molecules by Lp(a)14, the deposit of Lp(a) 
in the arterial wall and the prothrombotic effect caused by the homology of apo(a) to plasminogen are potential 
mechanisms by which Lp(a) raises cardiovascular (CV) risk15,16. After migration from plasma into the arterial 
intima, Lp(a) joins to the extracellular matrix through both apo(a) and apoB components, resulting in the grow-
ing of the atherosclerotic plaque17.
In 2010, the European Atherosclerosis Society (EAS) Consensus Panel recommended a target level for 
Lp(a) < 50 mg/dL, as a feature of global CV risk18. The treatment of choice for the patients with increased Lp(a) 
levels is niacin or nicotinic acid (1–3 g/day), as recommended by the European Society of Atherosclerosis (EAS) 
and American Heart Association (AHA)/American Stroke Association (ASA) guidelines18,19. However, after neg-
ative trials with niacin, statins are worldwide recommended to reduce the global CV risk20. Moreover, observa-
tional studies suggested that the enhanced CV risk associated with increased Lp(a) levels is no longer observed 
when LDL-C levels are treated to aggressive levels, suggesting intensification of statin therapy and LDL-C lower-
ing as a potential option in subjects with Lp(a) elevation13,20. Niacin therapy produces side-effects via stimulation 
of prostaglandin D(2) and E(2) synthesis, posing another obstacle to its use for Lp(a) elevation in clinical prac-
tice21. Therefore, a new therapy to target high Lp(a) levels is considered an important and unmet clinical need22. 
Besides niacin and intensive statin therapy, tibolone has also been investigated in patients with elevated Lp(a) 
levels23. Other drugs currently under development include cholesteryl ester transfer protein (CETP) inhibitors24, 
proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitory monoclonal antibodies24,25, mipomersen, an 
antisense oligonucleotide (ASO) against apoB mRNA26, eprotirome, a thyroid analogue27, lomitapide, a micro-
somal triglyceride transfer protein inhibitor28, and ASO therapy (ISIS APO(a) Rx) directly against apo(a)29,30. In 
addition, there has been a surge of interest to screen natural products (nutraceuticals/functional foods) for their 
effects on Lp(a) concentration31,32.
Different studies have indicated that L-carnitine, an amino acid involved in mitochondrial fatty acid oxida-
tion and ATP production, might be associated with reduction in Lp(a) levels33. The metabolism of L-carnitine is 
complex, and involves formation of many short and long chain acylated forms, as well as metabolism to its core 
structure31–33. In addition, there are substantial alterations in the metabolism of L-carnitine depending upon 
whether it is provided as intravenous supplement, such as during hemodialysis, or as oral supplement34. With the 
latter route of supplementation, gut microbes have been shown to significantly impact L-carnitine metabolism, 
and to convert it into alternative metabolites, linked to increased atherosclerosis risk35,36.
Therefore, we aimed to assess the impact of L-carnitine supplementation and type of administration on 
plasma Lp(a) concentrations through systematic review of literature and meta-analysis of available randomized 
controlled trials (RCTs).
Methods
Search Strategy. This study was designed according to the guidelines of the 2009 preferred reporting 
items for systematic reviews and meta-analysis (PRISMA) statement37. SCOPUS (http://www.scopus.com) and 
Medline (http://www.ncbi.nlm.nih.gov/pubmed) databases were searched and the search was limited to the 
randomized controlled studies (RCTs) carried out up to January 31, 2015 investigating the potential effects of 
L-carnitine supplementation on Lp(a) concentrations. The databases were searched using the following search 
terms in titles and abstracts (also in combination with MESH terms): (L-carnitine) AND Lp(a), or (L-carnitine) 
AND Lipoprotein(a). The wild-card term “*” was used to increase the sensitivity of the search strategy. No lan-
guage restriction was used in the literature search. The search was limited to studies in human. Selected articles 
were searched to identify further relevant studies. Two reviewers (CS and AS) evaluated each article separately. 
Disagreements were resolved by agreement and discussion with a third party (MB).
Study Selection. Original studies were included if they met the following inclusion criteria: (i) being a ran-
domized controlled trial with either parallel or cross-over design, (ii) investigating the impact of L-carnitine on 
plasma/serum concentrations of Lp(a), and, (iii) presentation of sufficient information on Lp(a) concentrations 
at baseline and at the end of follow-up in each group or providing the net change values.
Exclusion criteria were: (i) non-randomized trials, (ii) lack of an appropriate control group in the study design, 
(iii) observational studies with case-control, cross-sectional or cohort design, (iv) lack of sufficient information 
on baseline or follow-up Lp(a) concentrations, (v) inability to obtain adequate details of study methodology or 
results from the article or the investigators, and, (vi) the study was ongoing.
Data extraction. Eligible studies were reviewed and the following data were abstracted: (1) first author’s 
name, (2) year of publication, (3) study location; (4) study design; (5) number of participants in the L-carnitine 
and control (in case of randomized design) groups, (6) age, gender and body mass index (BMI) of study partici-
pants, (7) baseline levels of total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:19188 | DOI: 10.1038/srep19188
high-sensitivity C-reactive protein (hsCRP) and glucose, (8) systolic and diastolic blood pressures, and, (9) data 
regarding baseline and follow-up concentrations of Lp(a).
Quality assessment. A systematic assessment of bias in the included studies was performed using the 
Cochrane criteria38. The items used for the assessment of each study were as follows: adequacy of sequence gener-
ation, allocation concealment, blinding, and handling of dropouts (incomplete outcome data), selective outcome 
reporting, and other potential sources of bias. According to the recommendations of the Cochrane Handbook, a 
judgment of “yes” indicated low risk of bias, while “no” indicated high risk of bias. Labeling an item as “unclear” 
indicated an unclear or unknown risk of bias.
Quantitative Data Synthesis. Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) 
V2 software (Biostat, NJ)39. Net changes in measurements (change scores) were calculated as follows: measure 
at end of follow-up − measure at baseline. For single-arm cross-over trials, net change in plasma concentrations 
of L-carnitine was calculated by subtracting the value after control intervention from that reported after treat-
ment. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square 
root [(SDpre-treatment)2 + (SDpost-treatment)2 − (2 R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient 
(R) = 0.5. If the outcome measures were reported in median and inter-quartile range, mean and standard SD 
values were estimated using the method described by Hozo et al.40. Where standard error of the mean (SEM) was 
only reported, standard deviation (SD) was estimated using the following formula: SD = SEM × square root (n), 
where n is the number of subjects.
Meta-analysis was performed using either a fixed-effects or random-effect model according to the I2 statistic. 
I2 values < 50% and ≥ 50% corresponded with the use of fixed-effects and random-effects model, respectively. 
The generic inverse variance method was used to weight each individual study included in the meta-analysis. 
Heterogeneity was quantitatively assessed using the I2 index. Effect sizes were expressed as weighted mean dif-
ference (WMD) and 95% confidence interval (CI). In order to evaluate the influence of each study on the overall 
effect size, a sensitivity analysis was conducted using the leave-one-out method (i.e., removing one study each 
time and repeating the analysis).
Publication bias. Potential publication bias was explored using visual inspection of Begg’s funnel plot asym-
metry, and Begg’s rank correlation and Egger’s weighted regression tests. Duval & Tweedie’s “trim and fill” method 
was used to adjust the analysis for the effects of publication bias41.
Results
Search results and trial flow. The initial screening for possible interpretation eliminated the articles whose 
titles and/or abstracts were clearly insignificant. After evaluation, 7 studies with 8 treatment arms (intravenous 
administration: 2 eligible studies with 3 treatment arms, oral administration: 5 eligible studies with 5 treatment 
arms) met the inclusion criteria and were chosen for the final meta-analysis. A study flow chart is presented on 
Fig. 1.
Characteristics of included studies. In total, 375 participants were randomized, of whom 200 were 
assigned to the L-carnitine supplementation group and 175 to the control group. The number of participants 
in these trials ranged from 15 to 46. Studies were published between 2000 and 2014, and were conducted in 
the Italy, China and Iran. A range of doses from 1 g 3 times per week to 4 g/day of L-carnitine was administered 
in the included trials. Duration of L-carnitine supplementation ranged from 1 week to 24 weeks. L-carnitine 
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis. 
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appeared safe and well-tolerated in all RCTs included in this analysis, with no report of any serious adverse events. 
Demographic and baseline parameters of the included studies are shown in Table 1.
Risk of bias assessment. According to the Cochrane Collaboration, a specific tool for assessing risk of bias 
in each included study comprises judgment of specific features of the study42. This involves evaluating the risk 
of bias as ‘low risk’, ‘high risk or ‘unclear risk’. The final category implies either lack of information or doubt over 
the potential for bias. There are seven analyzed domains comprising: sequence generation (selection bias), alloca-
tion sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding 
Figure 2. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of 
L-carnitine on plasma Lp(a) concentrations. Lower plot shows leave-one-out sensitivity analysis.
Figure 3. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of 
oral L-carnitine on plasma L(a) concentrations. Lower plot shows leave-one-out sensitivity analysis.
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Study Derosa et al.63 Galvano et al.64 Shakeri et al.65 Shojaei et al.66 Sirtori et al.67 Solfrizzi et al.68 Zhang et al.69
Year 2003 2009 2010 2011 2000 2006 2014
Location Italy Italy Iran Iran Italy Italy China
Design
Randomized, double-
masked, placebo-
controlled clinical trial,
Double-blind, 
randomized clinical 
trial
Unblinded, 
randomized 
clinical trial
Randomized 
double-blind 
placebo-
controlled 
clinical trial
Randomized 
double-blind 
placebo-
controlled 
clinical trial
Open, randomized, 
parallel-group study
Randomized, 
single-blind 
placebo 
controlled 
clinical study
Duration of study 24 weeks 16 weeks 12 weeks 12 weeks 12 weeks 60 days 1 week
Inclusion criteria
Patients with newly 
diagnosed (within 6 
months) type 2 DM 
managed through 
dietary restriction 
alone and with 
hypercholesterolemia 
Lp(a) level,> 30 mg/dL
Patients aged 30 – 
70 years with type 
2 DM, that was 
managed through 
dietary restriction 
alone, and with 
dyslipidemia 
(defined as 
LDL-C > 100 mg/
dl, HDL-C < 40 mg/
dl and/or 
tot-C > 200 mg/
dl) and Lp(a) levels 
> 20 mg/dl
Hemodialysis 
patients in the 
age range of 24 
to 80 years
Maintenance 
hemodialysis 
patients with 
moderately 
high serum 
lipoprotein(a) 
levels being on 
treatment with 
atorvastatin 
and/or 
lovastatin (both 
20 mg/d)
Patients with 
plasma Lp(a) 
levels ranging 
between 40 
and 80 mg/dl, 
characterized 
by additional 
hyperlipidemia
Patients with 
type 2 DM, a 
triglyceride serum 
levels < 400 mg/
dL (< 4.5 mmol/L), 
and Lp(a) serum 
levels > 20 mg/dL 
(> 0.71 mmol/L) 
at two consecutive 
measurements at 4 
and 5 weeks from 
the dietary lead-in 
period
Overweight or 
obese (body 
mass index 
[BMI] 28.2 
+ /− 1.8 kg/
m2) patients 
aged from 
27–65 years 
with metabolic 
syndrome
Route of administration oral NR oral intravenous oral oral intravenous
L-Carnitine Dose 2 g/day 2 g/day 1 g/day 1 g 3 times per week 2 g/day 2 g/day 4 g/day
Participants Case 46 38d 18 12a 18 26d 15
13b
14c
Control 48 37e 18 13 18 26d 15
Age (years) Case 52 (6) 52.1 ± 8.1d 54.5 ± 19.0 55.3 ± 15.6a 55.1 ± 7.4 65.4 ± 10.4d 46.9 ± 9.14
53.5 ± 11.5b
52.8 ± 10.4c
Control 50 (7) 51.4 ± 7.6e 57.0 ± 20.0 51.6 ± 19.2 57.8 ± 11.2 62.7 ± 8.74e 46.8 ± 10.9
Male (%) Case 52.2 39.47d 67 50a 66.6 50d 26.6
53.8b
42.8c
Control 47.9 40.54e 61 46.1 50 53.8e 33.3
BMI (kg/m2) Case 27.3 (2.5) 27.8 ± 2.0d 23 ± 4 24.3 ± 2.1a NR 29 (24.5–33)d 28.2 ± 1.8
23.6 ± 2.4b
23.3 ± 2.3c
Control 26.8 (2.2) 27.1 ± 2.4e 23 ± 3 23.6 ± 2.6 NR 27.8 (23.5–31)e 27.1 ± 2.3
hs-CRP (mg/L) Case NR NRd NR NRa NR NRd 3.06 ± 1.69
NRb
NRc
Control NR NRe NR NR NR NRe 2.3 ± 3.74
Total cholesterol (mg/dL) Case 235 (30) 261 ± 21d NR 147.1 ± 28.8a 277.1 ± 33.5 225.6 ± 35.4d 208.04 ± 35.57
150.9 ± 25.6b
152.5 ± 23.5c
Control 228 (4 I) 259 ± 24e NR 156.5 ± 31.9 262.3 ± 28.1 239.9 ± 57.9e 206.49 ± 44.08
LDL-C (mg/dL) Case 161 (16) 162.8 ± 16.4d NR 84.5 ± 26.5a NR 144.3 ± 34.6d 146.17 ± 37.12
89.5 ± 28.7b
83.2 ± 32.2c
Control 157 (19) 161.4 ± 18.1e NR 84.0 ± 13.9 NR 157 ± 54.2e 143.85 ± 41.76
HDL-C (mg/dL) Case 45 (4) 38.4 ± 0.8d NR 41.9 ± 7.8a 57 ± 17.4 41.2 ± 10.7d 42.92 ± 10.05
40.9 ± 3.2b
39.4 ± 7.0c
Control 43 (5) 38.2 ± 0.7e NR 42.8 ± 5.7 50.9 ± 13.4 41.1 ± 12.2e 44.47 ± 8.50
Triglycerides (mg/dL) Case 125 (35) 301 ± 24d NR 149.2 ± 75.2a 138.8 ± 38.3 189.5 ± 55.4d 152.34 ± 68.20
131.0 ± 53.2b
155.9 ± 62.6c
Control 156 (28) 298 ± 32e NR 150.9 ± 76.9 139.5 ± 54.5 209.7 ± 61.7e 149.69 ± 61.11
Glucose (mg/dL) Case 135 (30) 136 ± 27d NR NRa NR NRd 93.69 ± 10.99
NRb
Continued
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of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting 
(reporting bias) and other potential sources of bias (Table 2).
Effect of L-carnitine on plasma Lp(a) concentrations. Overall, the impact of L-carnitine on plasma 
Lp(a) levels were reported in 7 trials comprising 8 treatment arms with 375 participants. Meta-analysis suggested 
a significant reduction of Lp(a) levels following supplementation with L-carnitine (WMD: − 8.82 mg/dL, 95% 
CI: − 10.09, − 7.55, p < 0.001). This result was robust in the leave-one-out sensitivity analysis (Fig. 2). When 
the studies were categorized according to the route of administration, a significant reduction in plasma Lp(a) 
concentration was observed with oral (WMD: − 9.00 mg/dL, 95% CI: − 10.29, − 7.72, p < 0.001) (Fig. 3) but not 
intravenous L-carnitine supplementation (WMD: − 2.91 mg/dL, 95% CI: − 10.22, 4.41, p = 0.436). Both of these 
latter effects were robust in the sensitivity analysis (Fig. 4).
Effect of L-carnitine on plasma lipids. Overall, the impact of L-carnitine on plasma total cholesterol, 
LDL-C, HDL-C and triglycerides levels were reported in 7, 6, 6 and 6 treatment arms, respectively. Meta-analysis 
suggested a significant reduction in plasma concentrations of total cholesterol (WMD: − 9.49 mg/dL, 95% CI: 
− 17.07, − 1.92, p = 0.014) and a borderline significant trend in reduction of LDL-C (WMD: − 4.67 mg/dL, 95% 
CI: − 9.78, 0.45, p = 0.074) following L-carnitine supplementation (Fig. 5). However, plasma HDL-C (WMD: 
0.85 mg/dL, 95% CI: − 2.34, 4.05, p = 0.601) and triglycerides (WMD: − 2.42 mg/dL, 95% CI: − 34.85, 30.01, 
p = 0.884) were not altered by L-carnitine (Fig. 5).
Study Derosa et al.63 Galvano et al.64 Shakeri et al.65 Shojaei et al.66 Sirtori et al.67 Solfrizzi et al.68 Zhang et al.69
NRc
Control 141 (25) 137 ± 28e NR NR NR NRe 91.89 ± 16.57
SBP (mmHg) Case NR 149 ± 12d NR NRa NR NRd 120.6 ± 15.45
NRb
NRc
Control NR 150 ± 11e NR NR NR NRe 135.7 ± 15.6
DBP (mmHg) Case NR 80 ± 11d NR NRa NR NRd 78.9 ± 9.4
NRb
NRc
Control NR 79 ± 12e NR NR NR NRe 80.8 ± 8.4
Lp(a) (mg/dL) Case 29.6 (I 8.3) 29.7 ± 11.2d 76 ± 37 45.0 ± 23.9 45.4 ± 17.8 41 (34.0–64.0)d 23.34 ± 9.04
48.6 ± 22.8
50.3 ± 18.4
Control 27.8 (20.2) 29.5 ± 10.8e 61 ± 26 31.6 ± 7.7 54.1 ± 17.4 36.5 (25.3–49.0)e 27.34 ± 9.14
Table 1.  Demographic characteristics of the included studies. Values are expressed as mean ± SD or 
median (25–75 percentiles). ABBREVIATIONS: BMI: body mass index; Nr: not reported; LDL-C: low-density 
lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; hs-CRP: high-sensitivity C-reactive protein; BMI: body mass index; DM: diabetes 
mellitus; adenotes 1000 mg (L-carnitine, Carnivore, Sigma tau, Spain), 3 times per week, after each dialysis 
session; bdenotes oral coenzyme Q10, 100 mg/d (Pharmed-Tnt Inc, Canada); cdenotes a combinations of 
both carnitine and coenzyme Q10; ddenotes L-carnitine 2 g/day and simvastatin 20 mg; edenotes 20 mg/day 
simvastatin tablet.
Study Ref
Sequence 
gene-ration
Allocation 
concea-lment
Blinding of 
partici-pants 
and person-nel
Blinding 
of outcome 
assessment
Incom-plete 
outcome data
Selec-tive 
out-come 
repor-ting
Other 
poten-tial 
threats to 
validity
Derosa et al. 63 L U L L L L L
Galvano et al. 64 H U L L L L L
Shakeri et al. 65 U U H H L L L
Shojaei et al. 66 L U L L L L L
Sirtori et al. 67 L U L L L L L
Solfrizzi et al. 68 U U H H L L L
Zhang et al. 69 L H L L L L L
Table 2.  Assessment of risk of bias in the included studies using Cochrane criteria. L: low risk of bias;  
H: high risk of bias; U: unclear risk of bias.
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Meta-regression analysis. Potential associations between the Lp(a)-lowering effects of L-carnitine with 
dose and duration of supplementation were evaluated using meta-regression analysis. The results suggested that 
the pooled estimate is independent of L-carnitine dose (slope: − 0.30; 95% CI: − 4.19, 3.59; p = 0.878) and dura-
tion of treatment (slope: 0.18; 95% CI: − 0.22, 0.59; p = 0.374) (Fig. 6).
Publication bias. The funnel plot of the study standard error by effect size (WMD) was asymmetric, sug-
gesting potential publication bias that was also confirmed by the results of Egger’s linear regression test (inter-
cept = 1.08, standard error = 0.41; 95% CI = 0.09, 2.09, t = 2.61, df = 6, two-tailed p = 0.04) (Fig. 7). However, 
there was no sign of bias according to the Begg’s rank correlation test (Kendall’s Tau with continuity correc-
tion = 0.32, Z = 1.11, two-tailed p-value = 0.266). An attempt was made to adjust the effect size by imputing 
potentially missing studies using “trim and fill” correction. This approach led to the imputation of 3 missing trials 
on the left side of funnel plot, yielding a corrected effect size of − 9.16 mg/dL (95% CI: − 10.41, − 7.92) (Fig. 7). 
The “fail-safe N” test showed that 89 studies would be needed to bring the effect size down to a non-significant 
(p > 0.05) value.
Discussion
To our knowledge, the current systematic review and meta-analysis is the first to analyze evidence from RCTs on 
the efficacy of supplementation with L-carnitine on plasma Lp(a) concentrations. The results, albeit with small 
numbers of subjects overall, suggest a significant reduction of Lp(a) levels following oral supplementation with 
L-carnitine.
Figure 4. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of 
intravenous L-carnitine on plasma Lp (a) concentrations. Lower plot shows leave-one-out sensitivity analysis.
Figure 5. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of 
L-carnitine on plasma lipids. 
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L-carnitine, a derivate of the amino acid lysine, is found predominantly in red meat, certain fish, and trace 
levels observed in dairy and some plant foods, such as avocado43. The effects of L-carnitine on lipid metabo-
lism have been investigated in many experimental and clinical studies, but the exact mechanisms responsible 
for L-carnitine lowering effects on Lp(a) levels are not completely understood. However, the reason for these 
effects could be that L-carnitine, by stimulating fatty acid break-down in mitochondria, might reduce liver pro-
duction of Lp(a)43. An experimental study has shown that L-carnitine inhibits advanced glycation end products 
(AGE)-modification of bovine serum albumin more potent than aminoguanidine, a prototype inhibitor of AGE43. 
In hemodialysis patients, L-carnitine supplementation might play a protective role against vascular injury based 
on reduction in circulating levels of AGEs44.
Recent studies have showed that oral ingestion of L-carnitine in both animals and humans results in generation 
of trimethylamine by intestinal microbiota, which is absorbed and then metabolized to trimethylamine-N-oxide 
(TMAO) by liver flavin monoxygenases (FMOs) (especially FMO3 and FMO1)35,45. Since L-carnitine is contained 
in red meat, omnivorous humans have higher values of TMAO than vegetarians, explaining why L-carnitine and 
the microbiota may contribute to the causal link between high consumption of red meat and CV risk35. Recent 
metabolomics and animal studies showed that TMAO, an intestinal microbiota-dependent metabolite formed 
from dietary trimethylamine-containing nutrients such as phosphatidylcholine (PC), choline, and carnitine, is 
linked to coronary artery disease pathogenesis, only in the presence of TMA/TMAO generation and intact gut 
microbiota35,46. The mechanisms by which TMAO raises CV risk and accelerates atherosclerosis are not well 
understood, but studies have shown that TMAO arising from both choline and L-carnitine supplementation in 
mice may inhibit reverse cholesterol transport35 and enhance foam cell formation in both arterial and peritoneal 
cavity47. Direct provision of TMAO into diet has been shown to increase the development of atherosclerosis in 
animal models, confirming its pro-atherogenic properties47, and multiple clinical studies have confirmed that an 
elevated TMAO level is associated with increased risks for incident major adverse CV events48.
The levels of TMAO are modulated by hepatic FMO3, which is regulated by a bile acid-activated nuclear 
receptor named the farnesoid X receptor (FXR)49. The FMOs are known to oxidize sulfur-, phosphorus-, and 
selenium-containing compounds and endogenous amines, including TMA50. Antisense oligonucleotide mediated 
suppression of FMO3 levels have recently been shown to suppress TMAO levels, and to inhibit atherosclerosis in 
animal models51. Furthermore, FMO3 has been shown to serve as a central regulator of tissue cholesterol balance, 
and to be involved in insulin resistance and dyslipidemic changes in mouse models, suggesting the FMO3 and 
TMAO pathway as potential mediators of diabetes associated atherosclerosis52,53.
In contrast to the potential dangerous effects in the acceleration of atherosclerosis, mixed results have been 
reported with L-carnitine supplementation in the immediate setting following an acute myocardial infarction 
(AMI). While the major RCTs examining L-carnitine supplementation in the immediate post-MI setting showed 
no clinical benefit, a meta-analysis of L-carnitine intervention studies suggested its potential beneficial effect54. 
Other studies have suggested beneficial effects of L-carnitine supplementation on inflammatory parameters55, in 
the secondary prevention of CVD54,56, in diabetes mellitus57, on serum lipid profile in hemodialysis patients58, for 
adults with end-stage kidney disease on hemodialysis59 or for patients in maintenance hemodialysis60, though 
detailed analysis of whether the carnitine was provided in oral vs intravenous supplementation, bypassing the gut 
microbiota, has not been extensively evaluated. In our meta-analysis, L-carnitine significantly reduced total cho-
lesterol and showed borderline significant reduction of LDL-C, while plasma HDL-C and triglycerides were not 
Figure 6. Meta-regression plots of the association between mean changes in plasma Lp(a) concentrations 
after L-carnitine treatment with dose and duration of treatment. 
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affected. According to the available data L-carnitine supplementation might also significantly reduce triglycerides 
levels, but especially when low HDL-C levels are present61. However, the real effects of L-carnitine supplemen-
tation, taking into account its above-mentioned positive and possibly negative properties (via TMAO), on the 
process of atherosclerosis and atheroma plaque merit further investigations.
This meta-analysis has several important limitations, and the obtained results should be viewed as sugges-
tive only. Most notable, there were only few eligible RCTs included in this meta-analysis, and most of them had 
a relatively modest number of participants. Moreover, none of the RCTs included have hard clinical outcome 
endpoints, and the duration of the interventions was relatively modest. Furthermore, the included studies were 
heterogeneous concerning the characteristics of patients and study design (2 of studies on L-carnitine supple-
mentation have been performed in the setting of hemodialysis when carnitine metabolism is altered in uremia 
and the depletion of carnitine is expected62, 4 in diabetic/metabolic syndrome patients with dyslipidemia, and 1 
in hyperlipidemic patients). There was also the diversity of the co-administered medications (statins or coenzyme 
Q10). Moreover the duration of the L-carnitine supplementation differs from one study to another, therefore 
further studies are required to test the time dependence of the observed effect as well as the impact of L-carnitine 
bioavailability on the Lp(a)-lowering activity. Many characteristics that vary within studies, such as the type of 
study, the year of publication, the inclusion and exclusion criteria, the sample size, the control group or quality of 
the studies, could have been the factors of between-study heterogeneity. However, we used “leave-one-out” sen-
sitivity analysis under a conservative random-effects model to assess the possibility of some bias such as unclear 
double-randomization or large unbalanced dropout. Our results suggest that the significance of estimated pooled 
effect size is not biased by any single study.
The meta-analysis suggests that L-carnitine supplementation might be associated with significant Lp(a) lower-
ing. However, given the TMAO elevating effect of oral L-carnitine supplementation, whether or not L-carnitine is 
a reasonable therapy to reduce Lp(a) levels requires further long-term investigations with hard clinical endpoints 
such as AMI, stroke and mortality risks. Prospective trials are required to fully elucidate the clinical value of 
L-carnitine supplementation.
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